



## Evaluation Report for Category B, Subcategory 3.12 Application

**Application Number:** 2019-1390  
**Application:** New Product Labels - New Sites or Host  
**Product:** A22070 Fungicide  
**Registration Number:** 33798  
**Active ingredients (a.i.):** Azoxystrobin, pydiflumetofen and propiconazole  
**PMRA Document Number:** 3120567

### Purpose of Application

The purpose of this application was to register A22070 Fungicide, an end-use product to be used for the control of a variety of fungal diseases on turf.

### Chemistry Assessment

A22070 Fungicide is formulated as a suspension containing pydiflumetofen at a concentration of 10.2 g/L, azoxystrobin at 62.5 g/L and propiconazole at 104 g/L. This end-use product has a density of 1.012 g/mL and pH of 6.7 for a 1% aqueous dilution. The required chemistry data for A22070 Fungicide have been provided, reviewed and found to be acceptable.

### Health Assessments

A22070C Fungicide is of slight acute oral, dermal and inhalation toxicity in rats. It is moderately irritating to the eye and skin of the rabbit. It is not a dermal sensitizer in mice.

No risks of concern to mixers/loaders, applicators, postapplication workers, golfers and bystanders are expected from the use on turf, provided that workers follow the label directions and wear the personal protective equipment identified on the label.

A dietary exposure assessment was not required for this application.

### Environmental Assessment

The A22070 Fungicide use pattern fits within the currently registered use pattern for other products containing pydiflumetofen, azoxystrobin, and propiconazole. No additional risk to the environment is expected from the registration of this product that cannot be mitigated through labelling.

## **Value Assessment**

The applicant submitted rationales to support the registration of A22070 Fungicide. Based on these rationales, the extrapolation of uses from precedent products to the label of A22070 Fungicide is supported. The registration of A22070 Fungicide will provide turfgrass managers with an additional product with broad-spectrum disease control while also potentially contributing to reducing the risk of resistance developing for dollar spot and fusarium patch by providing multiple modes of action.

## **Conclusion**

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information sufficient to support the registration of A22070 Fungicide.

## References

<b>PMRA Document Number</b>	<b>References</b>
2982792	2018, A22070C - Document H, DACO: 3.2.1,3.3.1,3.3.2 CBI
2982793	2018, A22070C- SF-966/1- Determination of CGA64250 (CGA93590-cis and CGA93591-trans diastereomers), ICI5504, SYN545974 in A22070C by HPLC, DACO: 3.4.1 CBI
2982794	2019, A22070C - Validation of Analytical Method SF-966/1, DACO: 3.4.1 CBI
2982795	2018, A22070C - Physico-Chemical Studies of the Formulation, DACO: 3.5.1,3.5.10,3.5.11,3.5.12,3.5.14,3.5.2,3.5.3,3.5.6,3.5.7,3.5.8,3.7 CBI
3102261	2020, Chemical and Physical Properties, DACO: 3.5 CBI
2982797	2018, Azoxystrobin/Propiconazole/Pydiflumetofen SE (A22070C) - Acute Oral Toxicity - Up-And-Down Procedure in Rats, DACO: 4.6.1
2982798	2018, Azoxystrobin/Propiconazole/Pydiflumetofen SE A22070C - Acute Inhalation Toxicity in Rats, DACO: 4.6.3
2982799	2018, Azoxystrobin/Propiconazole/Pydiflumetofen SE A22070C - Primary Eye Irritation in Rabbits, DACO: 4.6.4
2982800	2018, Azoxystrobin/Propiconazole/Pydiflumetofen SE (A22070C) - In Vitro Eye Irritation Test in Isolated Chicken Eyes, DACO: 4.6.4
2982801	2018, Azoxystrobin/Propiconazole/Pydiflumetofen SE A22070C - Primary Skin Irritation in Rabbits, DACO: 4.6.5
2982802	2018, Azoxystrobin/Propiconazole/Pydiflumetofen SE (A22070C) - In Vitro Skin Irritation Test in the EPISKINTM Model, DACO: 4.6.5
2982803	2018, Azoxystrobin/Propiconazole/Pydiflumetofen SE (A22070C) - In Vitro Skin Corrosivity Test in the EPISKINTM Model, DACO: 4.6.5
2982806	2018, Azoxystrobin/Propiconazole/Pydiflumetofen SE A22070C – Local Lymph Node Assay (LLNA) in Mice, DACO: 4.6.6

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2020

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.